Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

HEPA

Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:HEPA
FechaHoraFuenteTítuloSímboloCompañía
19/04/202415:30GlobeNewswire Inc.Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialNASDAQ:HEPAHepion Pharmaceuticals Inc
16/02/202408:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
16/02/202407:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsNASDAQ:HEPAHepion Pharmaceuticals Inc
14/02/202414:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HEPAHepion Pharmaceuticals Inc
03/01/202416:15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at NASH-TAG 2024NASDAQ:HEPAHepion Pharmaceuticals Inc
07/12/202307:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
28/11/202315:15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNASDAQ:HEPAHepion Pharmaceuticals Inc
13/11/202315:05GlobeNewswire Inc.Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNASDAQ:HEPAHepion Pharmaceuticals Inc
10/11/202307:50GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
08/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HEPAHepion Pharmaceuticals Inc
25/10/202307:30GlobeNewswire Inc.Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelNASDAQ:HEPAHepion Pharmaceuticals Inc
29/09/202307:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202315:05GlobeNewswire Inc.Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202307:00GlobeNewswire Inc.New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ProgramNASDAQ:HEPAHepion Pharmaceuticals Inc
19/09/202308:00GlobeNewswire Inc.Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerNASDAQ:HEPAHepion Pharmaceuticals Inc
18/09/202307:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HEPAHepion Pharmaceuticals Inc
14/09/202307:45GlobeNewswire Inc.Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisNASDAQ:HEPAHepion Pharmaceuticals Inc
06/09/202315:30GlobeNewswire Inc.Hepion Pharmaceuticals Announces Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
21/07/202315:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202315:45GlobeNewswire Inc.Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202307:22GlobeNewswire Inc.Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
24/05/202315:45GlobeNewswire Inc.Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesNASDAQ:HEPAHepion Pharmaceuticals Inc
22/05/202306:00GlobeNewswire Inc.Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH BiomarkersNASDAQ:HEPAHepion Pharmaceuticals Inc
19/05/202315:05GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
12/05/202315:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HEPAHepion Pharmaceuticals Inc
10/05/202310:15GlobeNewswire Inc.Hepion Pharmaceuticals, Inc. Announces Reverse Stock SplitNASDAQ:HEPAHepion Pharmaceuticals Inc
17/04/202315:15GlobeNewswire Inc.Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023NASDAQ:HEPAHepion Pharmaceuticals Inc
10/04/202315:52Edgar (US Regulatory)Annual Report (10-k)NASDAQ:HEPAHepion Pharmaceuticals Inc
03/04/202305:02Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:HEPAHepion Pharmaceuticals Inc
30/03/202307:45GlobeNewswire Inc.Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLsNASDAQ:HEPAHepion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:HEPA